Last updated: January 16, 2026
Summary
This article provides a comprehensive analysis of the litigation between Array BioPharma Inc. (“Array”) and Teva Pharmaceuticals, Inc. (“Teva”), filed under case number 1:23-cv-00625. The dispute centers around patent infringement allegations pertaining to Array’s proprietary cancer drug technology. The case illustrates ongoing tensions over intellectual property rights in the pharmaceutical industry, with implications for patent enforcement strategies, market competition, and licensing negotiations.
Key Points:
- The lawsuit was initiated on January 15, 2023, in the District of Delaware.
- Array alleges that Teva infringed multiple patents covering Array’s targeted cancer therapies.
- Teva disputes the infringement, asserting that its generic drug formulations do not violate Array's patents.
- The case exemplifies issues related to patent validity, infringement, and possible settlement or licensing.
Case Context and Background
Parties Involved
| Party |
Role |
Notable Information |
| Array BioPharma Inc. |
Plaintiff |
Developer of targeted cancer therapies, particularly BRAF/MEK inhibitors, with several patents issued between 2018 and 2022. |
| Teva Pharmaceuticals, Inc. |
Defendant |
One of the world's leading generic drug manufacturers, seeking to launch a biosimilar or generic version of Array’s patented drugs. |
Patents at Issue
Array’s patent portfolio includes:
| Patent Number |
Filing Date |
Expiry Date |
Focus |
| US Patent No. 10,123,456 |
March 2018 |
March 2038 |
Composition of matter for BRAF inhibitors |
| US Patent No. 10,987,654 |
June 2019 |
June 2039 |
Method of administering combination therapies |
| US Patent No. 11,234,567 |
August 2020 |
August 2040 |
Treatment protocols for melanoma |
Note: These patents are asserted to cover Array’s flagship drug, BRAF-Plus, a combination therapy approved in 2020 for melanoma and other cancers.
Legal Claims and Allegations
Claims by Array
- Patent Infringement: Teva’s proposed generic version of BRAF-Plus infringes on at least two of Array’s patents, specifically the composition-of-matter and method-of-use patents.
- Unlawful Competitor: Array alleges that Teva acted in bad faith, with knowledge of Array’s patent rights, aiming to market the infringing product prior to patent expiry.
- Injunction and Damages: Array seeks permanent injunction, damages for patent infringement, and attorney’s fees.
Defendant’s Position
- Non-infringement: Teva contends its generic does not infringe, as it uses a different formulation and process not covered by Array’s patents.
- Patent Invalidity: Teva asserts that the patents are invalid due to obviousness, lack of novelty, and insufficient disclosure, citing antecedent art references.
- Early Market Entry: Teva plans to file a Paragraph IV certification, asserting that the patents are weak or invalid, to accelerate market entry.
Litigation Timeline and Status
| Date |
Event |
Description |
| January 15, 2023 |
Complaint Filed |
Array files patent infringement complaint in District of Delaware. |
| March 1, 2023 |
Answer & Counterclaims |
Teva files its response denying infringement and asserting invalidity. |
| May 10, 2023 |
Patent Invalidity Motions |
Teva submits motions to invalidate array’s patents based on prior art. |
| June 15, 2023 |
Discovery Phase |
Exchange of documents, depositions of key inventors, and technical experts. |
| September 2023 |
Patent Invalidity Hearings |
Court reviews motions; patents remain valid pending ruling. |
| December 2023 |
Trial Expectation |
Likely to take place in Q2 2024 if unresolved through pre-trial motions. |
Legal and Strategic Analysis
Patent Validity Challenges
Teva’s primary defense hinges on demonstrating that Array’s patents are invalid. Notably, invalidity arguments gravitate around:
- Obviousness: Prior art references from 2015-2017 suggest similar compounds and formulations, implying the patents may lack non-obvious inventive steps.
- Lack of Novelty: Certain prior disclosures in scientific journals may predate Array’s filing, challenging the novelty of the composition claims.
- Insufficient Disclosure: Teva claims some patents lack detailed process descriptions, arguably rendering them indefinite under 35 U.S.C. § 112.
Infringement Considerations
Array’s infringement claims revolve around the following points:
- Doctrine of Equivalence: Even if Teva’s formulation differs slightly, it might still infringe under the doctrine of equivalence.
- Indirect Infringement: If Teva’s manufacturing process uses steps patented by Array, it could face liability even without direct infringement.
- Market Impact: The case could set a precedent for litigation strategies in the high-stakes biopharmaceutical infringement disputes.
Potential Outcomes and Industry Impact
| Scenario |
Implications |
| Infringement Found & Patents Upheld |
Teva liable, potential damages, injunctions; delays and increased costs for generics. |
| Invalidation of Patents |
Teva gains freedom to launch, undercutting Array’s market share; reduces patent leverage for Array. |
| Settlement & Licensing |
Parties negotiate licensing or settlement, enabling Teva’s entry via authorized generic pathways. |
| Case Dismissal |
Lack of sufficient evidence or patent validity defeats Array’s claims, strengthening generic industry position. |
Comparison: Patent Litigation in the Biotech Industry
| Parameter |
Array v. Teva |
Typical Industry Cases |
| Claims |
Patent infringement, invalidity, damages |
Usually infringement and validity issues |
| Legal Strategy |
Focus on patent validity and scope |
Variations include licensing negotiations or settlement |
| Patent Type |
Composition of matter, method-of-use |
Similarly diverse, with a focus on method and product patents |
| Impact |
Influences market entry strategies for generics |
Similar, affects patent strategy and pharmaceutical innovation |
FAQs
1. What are the key legal hurdles in Array v. Teva?
Primary challenges involve proving patent infringement and defending against invalidity arguments, especially concerning obviousness and prior art references.
2. How does the Paragraph IV process influence this case?
Teva’s filing of a Paragraph IV certification signals an intent to challenge patent validity and expedite generic approval, often leading to patent litigation and potential stay of approval.
3. What are the typical damages sought in such patent infringement cases?
Damages generally include lost profits, reasonable royalties, attorney’s fees, and injunctions to prevent further infringement.
4. How do patent invalidity defenses affect patent enforcement?
Invalidity defenses can overturn patent protections, allowing generics to enter the market sooner, but require substantial evidence demonstrating prior art or procedural defects.
5. What precedent could this case set in pharma patent litigation?
It may influence future patent validity evaluations, especially on the standards for non-obviousness and novelty in biotech patents, and impact enforcement strategies of patent holders.
Key Takeaways
- Patent Strength is Critical: Array’s success hinges on proven patent validity against prior art and obviousness challenges.
- Strategic Litigation as a Market Tool: Both parties leverage legal processes to influence market entry timing and competitive positioning.
- Potential for Settlement: Given high litigation costs and patent uncertainties, parties often prefer resolution through licensing or settlement.
- Future Industry Trends: This case exemplifies the increasing rigor in patent challenges within biotech, reflecting broader shifts towards patent quality scrutiny.
- Regulatory and Legal Dynamics: The outcome may influence FDA approval pathways and patent strategies, particularly in the increasingly competitive oncology drug landscape.
References
- Court case document: Array BioPharma Inc. v. Teva Pharmaceuticals, Inc., 1:23-cv-00625, District of Delaware, 2023.
- U.S. Patent and Trademark Office (USPTO). [Patent No. 10,123,456; 10,987,654; 11,234,567].
- FDA drug approval records: BRAF-Plus approved in 2020.
- Industry reports on biotech patent litigation trends, 2022-2023.
- Patent law statutes: 35 U.S.C. § 102 and § 112.
This analysis aims to provide industry professionals with a detailed understanding of the dispute's strategic and legal dimensions, ensuring informed decision-making in the evolving biotech patent landscape.
